incretin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-07 and is reviewed periodically as new material appears.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
=== Laver Cup === Zverev took part in the inaugural Laver Cup in Prague in 2017. He accrued four points by winning both of his singles matches for Team Europe as they defeated Team World 15–9. He played a more crucial role in 2018 and 2019, winning the clinching matches in both editions against Kevin Anderson and Milos Raonic respectively. In the 2021 edition in Boston, he defeated John Isner in three sets in his only match in Team Europe's 14–1 win. In 2024, Zverev returned to the Laver Cup after a two-year absence in which Team World had won both editions. He lost his first match to Taylor Fritz, but rebounded on the third day to win against Frances Tiafoe in a deciding match tie-break. In 2025, Zverev failed to win any matches against Team World, losing in straight sets to Alex de Minaur and Taylor Fritz, the latter contributing his sixth consecutive loss against the American and allowing Team World to secure their third Laver Cup title.
The Ural Cossack Host was formed from the Ural Cossacks, who had settled along the Ural River. Their alternative name, Yaik Cossacks, comes from the river's former name, changed by the government after Pugachev's Rebellion of 1773–1775. The Ural Cossacks spoke Russian, and identified as having primarily Russian ancestry, but also incorporated many Tatars into their ranks. In 1577, twenty years after Moscow had conquered the Volga from Kazan to Astrakhan, the government sent troops to disperse pirates and raiders along the Volga. Among them was Yermak Timofeyevich. Some escaped to flee southeast to the Ural River, where they joined the Yaik Cossacks. In 1580, they captured Saraichik. By 1591, they were fighting on behalf of the government in Moscow. Over the next century, they were officially recognized by the imperial government.
=== Xenobiotics === Numerous drugs can raise GGT levels, including phenobarbitone and phenytoin. GGT elevation has also been occasionally reported following nonsteroidal anti-inflammatory drugs (including aspirin), St. John's wort and kava.
An isopeptide bond is a type of amide bond formed between a carboxyl group of one amino acid and an amino group of another. An isopeptide bond is the linkage between the side chain amino or carboxyl group of one amino acid to the α-carboxyl, α-amino group, or the side chain of another amino acid. In a typical peptide bond, also known as eupeptide bond, the amide bond always forms between the α-carboxyl group of one amino acid and the α-amino group of the second amino acid. Isopeptide bonds are rarer than regular peptide bonds. Isopeptide bonds lead to branching in the primary sequence of a protein. Proteins formed from normal peptide bonds typically have a linear primary sequence. Amide bonds, and thus isopeptide bonds, are stabilized by resonance (electron delocalization) between the carbonyl oxygen, the carbonyl carbon, and the nitrogen atom. The bond strength of an isopeptide bond is similar to that of a peptide due to the similar bonding type. The bond strength of a peptide bond is around 300 kJ/mol, or about 70 kcal/mol. Amino acids such as lysine, glutamic acid, glutamine, aspartic acid, and asparagine can form isopeptide bonds because they all contain an amino or carboxyl group on their side chain. For example, the formation of an isopeptide bond between the sidechains of lysine and glutamine is as follows:
== Outcomes == Overall, it appears that quality of life was found to be significantly improved for people with pelvic organ prolapse after surgical or pessary management. It can be difficult to determine success when discussing the outcomes of surgical intervention for pelvic organ prolapse due to multiple factors that can define success, such as anatomic success versus patient-reported outcome measures. Improvement of symptoms after surgery appears to be more of a measure of success for patients themselves, than does anatomic success alone. The rate of pelvic organ prolapse recurrence following surgery depends on several factors, the most significant being patient age (patients younger than 60 years have higher likelihood of recurrence), POP-Q stage (POP-Q greater than 3 has higher likelihood of recurrence), surgeon's experience performing the procedure, and prior history of pelvic surgery. Additionally, the surgical approach, for instance vaginal versus abdominal, also affects recurrence rate. The rates of reoperation following pelvic organ prolapse surgery ranges from 3.4% to 9.7%. Reoperation rates appear to be higher with transvaginal mesh repair compared to other procedures, due in part to complications such as mesh exposure.
Sources: en.wikipedia.org
Most 1. Bundesliga goals scored: 72 – Vincenzo Grifo 8 May 2026 Highest transfer fee paid: €10 million for Baptiste Santamaria Highest transfer fee received: €60million for Johan Manzambi Youngest goalscorer: Matthias Ginter – 18 years, 2 days Player who has scored the most against club: Claudio Pizarro – 14 goals in 17 matches Biggest home win: 6–0 – against Rot-Weiß Erfurt on 24 August 1991 Biggest 1. Bundesliga home win: 5–0 – against Hansa Rostock on 17 September 1999, against VfL Bochum on 9 December 2000 and against SV Werder Bremen on 21 February 2025 Biggest away win: 6–0 – against Borussia Mönchengladbach on 5 December 2021 Biggest 1. Bundesliga away win: 6–0 – against Borussia Mönchengladbach on 5 December 2021 Biggest home loss: 0–6 – against Bayern Munich on 16 December 2003 and against Werder Bremen on 4 December 2004 and 21 November 2009 Biggest 1. Bundesliga home loss: 0–6 – against Bayern Munich on 16 December 2003 and against Werder Bremen on 4 December 2004 and 21 November 2009 Biggest away loss: 0–7 – against Bayern Munich on 10 September 2011 Biggest 1. Bundesliga away loss: 0–7 – against Bayern Munich on 10 September 2011
By the end of the 1990s, marketing and products began to take on a more retro approach. Former menu items, such as the Burger Family, were reintroduced, and marketing became more targeted toward the baby boomer generation. The Great Root Bear and (in English Canada) the "ba-dum ba-dum" theme were also retired from most advertising (the tuba theme is still used in French-language ads). A new restaurant design was introduced, featuring a bright orange and yellow exterior, reminiscent of the 1950s, while the interior is decorated with memorabilia associated with the same period. Existing restaurants were renovated to match the new style. Meanwhile, with malls in decline, A&W began to focus on opening new standalone restaurants, particularly in smaller markets where McDonald's was often the only major hamburger chain. The last drive-in style restaurant closed in 2000, in Langley, British Columbia.
== Further reading == Altschul, SF (1991). "Amino acid substitution matrices from an information theoretic perspective". Journal of Molecular Biology. 219 (3): 555–65. doi:10.1016/0022-2836(91)90193-A. PMC 7130686. PMID 2051488. Dayhoff, M. O.; Schwartz, R. M.; Orcutt, B. C. (1978). "A model of evolutionary change in proteins". Atlas of Protein Sequence and Structure. 5 (3): 345–352. Eddy, SR (2004). "Where did the BLOSUM62 alignment score matrix come from?". Nature Biotechnology. 22 (8): 1035–6. doi:10.1038/nbt0804-1035. PMID 15286655. S2CID 205269887. Henikoff, S; Henikoff, JG (1992). "Amino acid substitution matrices from protein blocks". Proceedings of the National Academy of Sciences of the United States of America. 89 (22): 10915–9. Bibcode:1992PNAS...8910915H. doi:10.1073/pnas.89.22.10915. PMC 50453. PMID 1438297.
transition, which has been considered for the creation of a transportable optical clock as all transitions necessary for clock operation can be addressed with direct diode lasers at common wavelengths. Some of the few practical uses of radium are derived from its radioactive properties. More recently discovered radioisotopes, such as cobalt-60 and caesium-137, are replacing radium in even these limited uses because several of these isotopes are more powerful emitters, safer to handle, and available in more concentrated form. The isotope 223Ra was approved by the United States Food and Drug Administration in 2013 for use in medicine as a cancer treatment of bone metastasis in the form of a solution including radium-223 chloride. The main indication of treatment is the therapy of bony metastases from castration-resistant prostate cancer. 225Ra has also been used in experiments concerning therapeutic irradiation, as it is the only reasonably long-lived radium isotope which does not have radon as one of its daughters. Radium was still used in 2007 as a radiation source in some industrial radiography devices to check for flawed metallic parts, similarly to X-ray imaging. When mixed with beryllium, radium acts as a neutron source. Up until at least 2004, radium-beryllium neutron sources were still sometimes used, but other materials such as polonium and americium have become more common for use in neutron sources. RaBeF4-based (α, n) neutron sources have been deprecated despite the high number of neutrons they emit (1.84×106 neutrons per second) in favour of 241Am–Be sources.
Sources: en.wikipedia.org
In 1999, National Semiconductor also put out feelers for selling if not the whole, then a majority stake of, its fabrication plant in South Portland, Maine. However, that did not come to fruition. On June 28, 2000, National Semiconductor and TSMC Taiwan signed an agreement that would allow transfer of advanced fabrication technologies from TSMC to the National Semiconductor fabrication plant in South Portland, Maine. On March 11, 2009, National announced plans to close its assembly and test plant in Suzhou, China, and its wafer fabrication plant in Arlington, Texas. On October 9, 2009, Brian Halla announced his retirement as National's CEO. He remains executive chairman. The company promoted Donald (Don) Macleod, who had previously served as the company's president and chief operating officer, to CEO.
==== Hepatitis ==== In this pattern, hepatocellular necrosis is associated with infiltration of inflammatory cells. There can be three types of drug-induced hepatitis. (A) viral hepatitis is the most common, where histological features are similar to acute viral hepatitis. (B) in focal or non-specific hepatitis, scattered foci of cell necrosis may accompany lymphocytic infiltration. (C) chronic hepatitis is very similar to autoimmune hepatitis clinically, serologically, and histologically.
FIFA.com shortlisted 12 goals for users to vote on as the goal of the tournament. The award was won by Cape Verde's Sidny Lopes Cabral for his equalizing goal in extra time during the round of 32 match against Argentina. Additionally, a "Superior Player of the Match" award was presented after each game to the player who delivered the most outstanding performance in, and had the greatest impact on, that match, as decided by a public online vote conducted by FIFA. The award was sponsored by Michelob Ultra. Muslim players, such as Mohamed Salah and Lamine Yamal, received a brandless trophy, out of respect for Islam's views on alcohol. Outside of the FIFA awards, Messi was named the tournament's best player by the International Federation of Football History and Statistics (IFFHS), who cited his eight goals and four assists across seven appearances as the basis for the distinction.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.